Compare GO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GO | IOVA |
|---|---|---|
| Founded | 1946 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.1M | 881.3M |
| IPO Year | 2019 | N/A |
| Metric | GO | IOVA |
|---|---|---|
| Price | $9.70 | $2.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $15.27 | $10.45 |
| AVG Volume (30 Days) | 2.2M | ★ 12.7M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,571,346,000.00 | $250,425,000.00 |
| Revenue This Year | $10.67 | $60.71 |
| Revenue Next Year | $5.13 | $59.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.22 | ★ 175.62 |
| 52 Week Low | $8.96 | $1.64 |
| 52 Week High | $19.41 | $6.16 |
| Indicator | GO | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 47.81 |
| Support Level | $9.06 | $2.25 |
| Resistance Level | $9.63 | $2.77 |
| Average True Range (ATR) | 0.43 | 0.22 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 65.94 | 31.01 |
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.